Taysha Gene Therapies Inc
Taysha Gene Therapies is a biotechnology company that develops gene therapies for the treatment of rare monogenic central nervous system disorders.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Taysha Gene Therapies' stock, expecting it to rise to $6.94.
Financial Health
Taysha Gene Therapies has modest revenue and cash flow, with a reasonable book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring TSHA
Gene Therapy's Regulatory Tailwind
Sarepta Therapeutics' stock surged after the FDA re-approved its gene therapy for muscular dystrophy, signaling a positive turn for the industry. This development creates a potential tailwind for other biotech companies specializing in novel treatments for rare genetic diseases.
Published: July 30, 2025
Explore BasketGene Therapy's Competitive Shift
The European Medicines Agency's recent rejection of Sarepta Therapeutics' gene therapy creates a potential opening for its competitors. This theme focuses on the biopharmaceutical companies that stand to benefit from this regulatory hurdle in the Duchenne muscular dystrophy market.
Published: July 25, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical programmes progress
Taysha’s value largely depends on trial outcomes and regulatory milestones, which can create opportunity but also binary downside risks.
Catalyst‑driven moves
Share price may react strongly to news such as trial readouts, partnerships or licensing deals, though performance can be volatile.
Manufacturing & access
Scaling gene‑therapy manufacturing and securing market access are crucial for long‑term value; these areas carry technical and commercial risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
